The patent for semaglutide, the active ingredient in Novo Nordisk’s Wegovy and Ozempic, expired in India this week-triggering a flood of generic alternatives from domestic pharma giants like Cipla, Sun Pharma, Dr Reddy’s, and Biocon.
Current monthly costs of $100-$170 are expected to plummet to $36-$54, making these GLP-1 receptor agonists accessible to millions of Indians. The country’s anti-obesity drug market, already growing from $16 million in 2021 to nearly $100 million, is poised for explosive expansion.
India, the world’s largest supplier of generic medicines, now stands to export billions in affordable semaglutide products-particularly to the U.S., where obesity drives demand. Analysts project the U.S. market alone could hit $10 billion within years.
These drugs, originally developed for diabetes, reduce appetite by mimicking gut hormones. They’re now used by cardiologists, orthopedists, and chest physicians to prepare patients for surgery and treat sleep apnea.
But experts warn: rapid weight loss without protein intake or exercise can cause muscle loss, facial wasting, and rebound hunger after discontinuation. Misuse is rising-gym trainers and beauty clinics are prescribing doses without medical oversight.
India’s drug regulator has issued warnings against direct-to-consumer advertising, stressing medical supervision. Doctors urge lifestyle changes before prescribing.
"These are powerful drugs," says Mumbai diabetologist Rahul Baxi. "We don’t want poor-quality generics to tarnish their reputation. Access must come with responsibility."
With over 77 million Type 2 diabetics and one of the world’s largest obese populations, India’s next phase isn’t just about cost-it’s about safe, sustainable scale.